Adding intismeran autogene to Keytruda lowered the risk of recurrence or death by 42%, but overall survival has not yet shown a significant difference.
Every dose is built for an audience of one. On Saturday, Oct. 24, investigators at the ESMO Congress 2026 in Madrid presented Phase 3 results showing that adding intismeran autogene, an individualized mRNA therapy, to pembrolizumab (Keytruda) after melanoma surgery lowered the risk of the cancer coming back or death compared with pembrolizumab alone [2][3].
The data reached the public before the podium did. Screenshots of the findings circulated on social media on Thursday, Oct. 22, according to BioPharma Dive [4], and ESMO said the embargo on the abstract had been breached [5]. Merck and Moderna released the topline figures that afternoon [1]. In the age of the screenshot, an embargo is apparently more of a suggestion.
Background
After high-risk melanoma is surgically removed, PD-1 immunotherapy is used to lower the chance of recurrence; in INTerpath-001, the comparator arm received up to about one year of pembrolizumab [1]. Add-on drugs have not beaten that backbone so far. "None of them has improved over PD-1," trial investigator Hussein Tawbi of MD Anderson told BioPharma Dive [4].
Intismeran, developed jointly by Merck and Moderna [1], takes a different approach. Each product is a synthetic mRNA encoding up to 34 neoantigens unique to the patient, identified by sequencing tumor and normal DNA [5]. The goal is to train the immune system to recognize mutations found only in that person's cancer.
What Was Found
INTerpath-001 enrolled 1,137 patients with completely resected stage IIB–IV cutaneous melanoma and randomized them 2:1 to intismeran plus pembrolizumab or placebo plus pembrolizumab [1]. Coverage of the full presentation reported 757 patients in the combination arm and 380 in the comparator arm, with a median follow-up of 24.6 months and a data cutoff of June 30, 2026 [2][3].
The primary endpoint, recurrence-free survival (RFS), favored the combination, with a hazard ratio (HR) of 0.58 (95% CI, 0.45–0.75; P<0.001), which the companies describe as a 42% reduction in the risk of recurrence or death [1]. At two years, 82.2% of patients in the combination arm were alive and recurrence-free, compared with 70.0% on pembrolizumab alone [1].
Distant metastasis-free survival, a key secondary endpoint, also improved: HR 0.62 (95% CI, 0.45–0.85; P=0.002), with two-year rates of 88.5% versus 80.2% [1]. Median RFS and median distant metastasis-free survival were not reached in either arm [1].
Overall survival is a different story so far. The companies called the data immature but showing a favorable trend [1]. Conference coverage reported an HR of 0.77 (95% CI, 0.45–1.31; P=0.33), which did not meet the prespecified significance boundary [2][3].
A pre-specified analysis split the timeline. In the first six months, the RFS hazard ratio was 0.99 (95% CI, 0.66–1.49); after six months, it was 0.42 (95% CI, 0.30–0.58) [1]. Patients in the combination arm waited a median of 64 days for their first intismeran dose [2], since each product is made from the patient's own tumor sample [7].
Safety
Treatment-related adverse events occurred in 95.8% of patients on the combination and 90.0% on pembrolizumab alone; grade 3–5 treatment-related events occurred in 14.2% and 13.4%, respectively [1]. The most common side effects with the combination were fever (52.2% vs. 8.2%), injection-site pain (51.0% vs. 9.5%) and fatigue (38.5% vs. 29.7%) [2][6]. The companies reported no new safety signals [1]. Reports of discontinuation rates and deaths differed between conference summaries, so those figures are best taken from the full paper when it appears.
Study Design and Limitations
The trial was randomized, double-blind and placebo-controlled [1], which strengthens the RFS findings. Still, several caveats apply. The results so far come from a company press release and a conference presentation; the companies say the paper has been accepted by The New England Journal of Medicine [1], but it had not been published at the time of writing. Overall survival is immature and not statistically significant. Of 1,749 patients screened, 302 (17.3%) were excluded because their tumor sample was inadequate [2], a practical hurdle for a therapy built from tissue. Intismeran is co-developed by the two companies that reported the results [1]; detailed funding and conflict-of-interest disclosures were not available in the sources reviewed.
Investors had hoped for more. BioPharma Dive reported that some had expected a 40% to 50% reduction in recurrence or death, and that Moderna shares fell nearly 25% on the news [4].
Clinical and Patient Implications
Intismeran is not approved anywhere. Presenter Georgina V. Long of Melanoma Institute Australia [2] called the results a "new benchmark for adjuvant treatment of melanoma" [1]. Janice Mehnert of NYU Langone, a trial investigator [4], told Targeted Oncology the study showed "a similar sustained benefit in a much larger sample size, which is very reassuring" [5]. For patients, the trade-off on current evidence is fewer recurrences at two years, more fever and injection-site pain, and no proven survival gain yet.
What Comes Next
Merck and Moderna say they are engaging with regulatory authorities [1]; no filing timeline has been announced. The peer-reviewed NEJM paper, longer overall survival follow-up and complete safety tables will determine how much weight this result can carry.
This article is for informational purposes only and is not medical advice; readers should consult their clinician about their own care.
References
Merck & Co. and Moderna. Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA (pembrolizumab) at ESMO 2026 Presidential Symposium. Press release (Business Wire). October 22, 2026. https://www.merck.com/news/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium/
Cancer Network Staff. INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma. CancerNetwork. October 24, 2026. https://www.cancernetwork.com/view/interpath-001-data-detail-survival-subgroup-and-safety-findings-in-melanoma
Serani S. Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I. Targeted Oncology. October 24, 2026. https://www.targetedonc.com/view/esmo-2026-presidential-symposium-i-late-breaking-recap
Gardner J. Moderna, Merck shares fall on eagerly anticipated cancer vaccine results. BioPharma Dive. October 22, 2026. https://www.biopharmadive.com/news/moderna-merck-esmo-intismeran-melanoma-vaccine-results/833765/
Targeted Oncology Staff. Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence. Targeted Oncology. October 23, 2026. https://www.targetedonc.com/view/personalized-mrna-vaccine-intismeran-autogene-pembrolizumab-cuts-melanoma-recurrence
Adamou C. New Personalised mRNA Therapy Improves Melanoma Outcomes: ESMO 2026. EMJ. October 24, 2026. https://www.emjreviews.com/oncology/news/new-personalised-mrna-therapy-improves-melanoma-outcomes-esmo-2026/
Steinzor P. Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%. AJMC. October 22, 2026. https://www.ajmc.com/view/merck-moderna-cancer-vaccine-cuts-melanoma-recurrence-risk-by-42-
